Comprehensive suppression of all apoptosis-induced proliferation pathways as a proposed approach to colorectal cancer prevention and therapy
M Bordonaro, E Drago, W Atamna, DL Lazarova - PLoS One, 2014 - journals.plos.org
Mutations in the WNT/beta-catenin pathway are present in the majority of all sporadic
colorectal cancers (CRCs), and histone deacetylase inhibitors induce apoptosis in CRC …
colorectal cancers (CRCs), and histone deacetylase inhibitors induce apoptosis in CRC …
Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress
Chemotherapeutic regimens for the treatment of colorectal cancer generally include
oxaliplatin, although inherent and acquired resistance is common. One potential mediator of …
oxaliplatin, although inherent and acquired resistance is common. One potential mediator of …
Phase Ib results of the rational combination of selumetinib and cyclosporin A in advanced solid tumors with an expansion cohort in metastatic colorectal cancer
MEK inhibition is of interest in cancer drug development, but clinical activity in metastatic
colorectal cancer (mCRC) has been limited. Preclinical studies demonstrated Wnt pathway …
colorectal cancer (mCRC) has been limited. Preclinical studies demonstrated Wnt pathway …
Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer
Background There is extensive evidence for the role of aberrant cell survival signaling
mechanisms in cancer progression and metastasis. Akt is a major component of cell survival …
mechanisms in cancer progression and metastasis. Akt is a major component of cell survival …
Phase I trial of regorafenib, hydroxychloroquine, and entinostat in metastatic colorectal cancer
TB Karasic, TJ Brown, C Schneider… - The …, 2022 - academic.oup.com
Background The antiangiogenic tyrosine kinase inhibitor regorafenib provides a survival
benefit in patients with previously treated metastatic colorectal cancer (CRC) …
benefit in patients with previously treated metastatic colorectal cancer (CRC) …
Erlotinib as 2nd and 3rd line monotherapy in patients with metastatic colorectal cancer. Results of a multicenter two-cohort phase II trial
U Keilholz, D Arnold, N Niederle, W Freier… - Journal of Clinical …, 2005 - ascopubs.org
3575 Background: Erlotinib (E, TarcevaTM) is an orally active small molecule tyrosine
kinase inhibitor (TKI) targeted against the ErbB1 (EGFR/HER1) TK receptor. EGFR-directed …
kinase inhibitor (TKI) targeted against the ErbB1 (EGFR/HER1) TK receptor. EGFR-directed …
Intermittent versus continuous erlotinib with concomitant modified “XELOX”(q3W) in first‐line treatment of metastatic colorectal cancer: correlation with serum …
BACKGROUND This study evaluated the activity of 2 schedules of erlotinib in combination
with chemotherapy, and the prognostic significance of serum amphiregulin (AREG) and …
with chemotherapy, and the prognostic significance of serum amphiregulin (AREG) and …
Colon cancer: genomics and apoptotic events
C Rupnarain, Z Dlamini, S Naicker, K Bhoola - 2004 - degruyter.com
Colon cancer is the third most common cancer globally. The risk of developing colon cancer
is influenced by a number of factors that include age and diet, but is primarily a genetic …
is influenced by a number of factors that include age and diet, but is primarily a genetic …
Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status
S Gaur, L Chen, V Ann, WC Lin, Y Wang, VHS Chang… - Molecular Cancer, 2014 - Springer
Background Cancer is the result of a multistep process of genomic alterations, including
mutations in key regulatory proteins that result in loss of balanced gene expression and …
mutations in key regulatory proteins that result in loss of balanced gene expression and …
Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!
S Stintzing, HJ Lenz - Expert opinion on pharmacotherapy, 2013 - Taylor & Francis
Introduction: Increased understanding in intracellular signaling pathways leading to
carcinogenesis, proliferation, migration, invasion, angiogenesis, and anti-apoptosis of …
carcinogenesis, proliferation, migration, invasion, angiogenesis, and anti-apoptosis of …